About this Research Topic
Radiotheranostics refers to the combination of diagnostic and therapeutic radiopharmaceuticals that can be used to both identify and treat diseases, particularly cancer. The field is emerging rapidly over the past decade with the development of new radiopharmaceuticals, improved imaging techniques, and an increased understanding of how radio theranostic can be used to personalize cancer treatment. Advances in radiotheranostics have been driven in part by the development of new radiopharmaceuticals, which are compounds that combine a radioactive isotope with a targeting molecule. These radiopharmaceuticals can be used for both diagnostic and therapeutic purposes. For example, PSMA-targeted radiopharmaceuticals have shown promise in the diagnosis and treatment of prostate cancer (PSMA-617), while radiolabeled somatostatin analogs have been used to diagnose and treat neuroendocrine tumors (DOTATATE).
In recent years, there has been a significant increase in the development and clinical use of radiotheranostics. This has led to a growing need for research in this field, with a particular focus on the development of new radiopharmaceuticals, preclinical and clinical evaluation, and optimization of treatment protocols.
This Research Topic aims to provide a comprehensive overview of the current state of radiotheranostics research, covering a range of themes such as the latest advances in radiopharmaceutical design and synthesis, preclinical and clinical evaluation of radiotheranostics, imaging techniques used in radiotheranostics, and the optimization of treatment protocols. The articles in this collection will cover a wide range of topics, including the latest advances in imaging technologies such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Additionally, this Topic will explore the potential clinical applications of radiotheranostics, including its use in cancer therapy, neurology, and cardiology. The articles published within this collection will be contributed by leading researchers in the field of radiotheranostics, providing a unique perspective on the current state of the field and its future directions. Overall, this Research Topic will serve as a valuable resource for researchers, clinicians, and other healthcare professionals interested in the latest developments in radiotheranostics.
In recent years, there has been a significant increase in the development and clinical use of radiotheranostics. This has led to a growing need for research in this field, with a particular focus on the development of new radiopharmaceuticals, preclinical and clinical evaluation, and optimization of treatment protocols.
This Research Topic aims to provide a comprehensive overview of the current state of radiotheranostics research, covering a range of themes such as the latest advances in radiopharmaceutical design and synthesis, preclinical and clinical evaluation of radiotheranostics, imaging techniques used in radiotheranostics, and the optimization of treatment protocols. The articles in this collection will cover a wide range of topics, including the latest advances in imaging technologies such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Additionally, this Topic will explore the potential clinical applications of radiotheranostics, including its use in cancer therapy, neurology, and cardiology. The articles published within this collection will be contributed by leading researchers in the field of radiotheranostics, providing a unique perspective on the current state of the field and its future directions. Overall, this Research Topic will serve as a valuable resource for researchers, clinicians, and other healthcare professionals interested in the latest developments in radiotheranostics.
Keywords: radiotheranostics, radiopharmaceuticals, diagnostic, therapeutic, PET, SPECT, MRI
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
